3.05.2006
what some people say.... and DNA implanting
just saw the film aeon flux with Charlize Theron, no choice really as it ran right on the inflight screen. What happens to a society where cloning has become an accepted coping strategy and means to life extension, where there is a keeper of DNA who recycles the DNA upon the instant of morbidity by immediately inputting an individual's DNA into a new candidate? As a result, there are no new people....visualization and speed are key themes - like brain speed and Tracking; here are some user comments on the relevant sight-speed test [measures your ability to track an object L - R and R - L in addition to brain speed].
----
diamond -1 points 11 days ago
Cool! I scored 172.5 ms, which I assume is good because the listed average is 351 ms.
borland 1 point 11 days ago
168.5 for me... all those years of playing quake weren't entirely useless it seems :-)
krid 1 point 10 days ago
-1, it wants my email address
bustlinSlug 1 point 10 days ago
149.1 for me.
UC-Irvine Researchers Identify Substance that Can Block Alzheimer's
Irvine, Calif. -- Researchers at UC Irvine have found that a new compound not only relieves the cognitive symptoms of Alzheimer's disease, but also reduces the two types of brain lesions that are hallmarks of this devastating disease, thereby blocking its progression.
In a study with genetically modified mice, a team of UCI researchers led by Frank LaFerla, professor of neurobiology and behavior, found that a compound known as AF267B, developed by paper co-author Abraham Fisher of the Israel Institute for Biological Research, reduced both plaque lesions and tangles in brain regions associated with learning and memory. Although drugs exist on the market today to treat the symptoms of Alzheimer's, AF267B represents the first disease-modifying compound, meaning it appears to affect the underlying cause and reduces the two signature lesions, plaques and tangles.
In a study with genetically modified mice, a team of UCI researchers led by Frank LaFerla, professor of neurobiology and behavior, found that a compound known as AF267B, developed by paper co-author Abraham Fisher of the Israel Institute for Biological Research, reduced both plaque lesions and tangles in brain regions associated with learning and memory. Although drugs exist on the market today to treat the symptoms of Alzheimer's, AF267B represents the first disease-modifying compound, meaning it appears to affect the underlying cause and reduces the two signature lesions, plaques and tangles.
